Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry

被引:2
|
作者
Riveira-Martin, Mercedes [1 ,2 ]
Struelens, Lara [3 ]
Iglesias, Jose Munoz [4 ]
Schoonjans, Werner [3 ]
Tabuenca, Olga [4 ]
Nogueiras, Jose Manuel [5 ]
Gomez, Francisco Javier Salvador [6 ]
Medina, Antonio Lopez [6 ,7 ]
机构
[1] Galicia Hlth Res Inst IISGS, Genet Oncol Radiobiol & Radiointeract Res Grp, Vigo, Spain
[2] Univ Complutense Madrid, Med Sch, Dept Radiol Rehabil & Physiotherapy, Madrid, Spain
[3] Belgian Nucl Res Ctr SCK CEN, Mol, Belgium
[4] Univ Hosp Vigo, Meixoeiro Hosp, Nucl Med Dept SERGAS, Vigo, Spain
[5] Univ Hosp Vigo, Meixoeiro Hosp, Nucl Med Dept GALARIA, Vigo, Spain
[6] Univ Hosp Vigo, Meixoeiro Hosp, Med Phys & RP Dept GALARIA, Vigo, Spain
[7] Univ Vigo, Dept Funct Biol & Hlth Sci, Vigo, Spain
关键词
Lu-177]Lu-DOTA-TATE; Occupational exposure; Nuclear medicine; Equivalent dose; RECEPTOR RADIONUCLIDE THERAPY; NEUROENDOCRINE TUMORS; LU-177; SAFETY; LU-177-DOTATATE; LU-177-OCTREOTATE;
D O I
10.1186/s40658-023-00592-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: The use of lutetium-177 (Lu-177)-based radiopharmaceuticals in peptide receptor nuclear therapy is increasing, but so is the number of nuclear medicine workers exposed to higher levels of radiation. In recent years, [Lu-177]Lu-DOTA-TATE has begun to be widely used for the treatment of neuroendocrine tumours. However, there are few studies evaluating the occupational radiation exposure during its administration, and there are still some challenges that can result in higher doses to the staff, such as a lack of trained personnel or fully standardised procedures. In response, this study aims to provide a comprehensive analysis of occupational doses to the staff involved in the administration of [Lu-177]Lu-DOTA-TATE.Results: A total of 32 administrations of [Lu-177]Lu-DOTA-TATE (7.4 GBq/session) carried out by a physician and a nurse, were studied. In total, two physicians and four nurses were independently monitored with cumulative (passive) and/or real-time (active) dosemeters. Extremity, eye lens and whole-body doses were evaluated in terms of the dosimetric quantities Hp(0.07), Hp(3) and Hp(10), respectively. It was obtained that lead aprons reduced dose rates and whole-body doses by 71% and 69% for the physicians, respectively, and by 56% and 68% for the nurses. On average, normalised Hp(10) values of 0.65 +/- 0.18 mu Sv/GBq were obtained with active dosimetry, which is generally consistent with passive dosemeters. For physicians, the median of the maximum normalised Hp(0.07) values was 41.5 mu Sv/GBq on the non-dominant hand and 45.2 mu Sv/GBq on the dominant hand. For nurses 15.4 mu Sv/GBq on the non-dominant and 13.9 mu Sv/GBq on the dominant hand. The ratio or correction factor between the maximum dose measured on the hand and the dose measured on the base of the middle/ring finger of the non-dominant hand resulted in a factor of 5/6 for the physicians and 3/4 for the nurses. Finally, maximum normalised Hp(3) doses resulted in 2.02 mu Sv/GBq for physicians and 1.76 mu Sv/GBq for nurses.Conclusions: If appropriate safety measures are taken, the administration of [Lu-177]Lu-DOTA-TATE is a safe procedure for workers. However, regular monitoring is recommended to ensure that the annual dose limits are not exceeded.
引用
收藏
页数:25
相关论文
共 50 条
  • [31] Safety and Dosimetry of [177Lu]Lu-DOTA-TATE in Adolescent Patients With Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors or Pheochromocytomas and Paragangliomas
    Giraudet, A.
    Handkiewicz-Junak, D.
    Hladun, R.
    Laetsch, T. W.
    Sorge, C.
    Sparks, R.
    Xu, L.
    Perraud, K.
    Kollar, G.
    Khanshan, F.
    Blumenstein, L.
    Brouri, F.
    Gaze, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S664 - S664
  • [32] Efficacy of [177Lu]Lu-DOTA-TATE in metastatic neuroendocrine neoplasms of different locations: our experience.
    Pudis, M.
    Vercher-Conejero, J. L.
    Martin-Marcuartu, J. J.
    Teule-Vega, A.
    Bondia-Bescos, S.
    Hervas-Sanz, B.
    Rodriguez-Gasen, A.
    Diaz-Moreno, J.
    Cortes-Romera, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S647 - S647
  • [33] Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [177Lu]Lu-OPS201 Compared to the Agonist [177Lu]Lu-DOTA-TATE
    Mansi, Rosalba
    Plas, Pascale
    Vauquelin, Georges
    Fani, Melpomeni
    PHARMACEUTICALS, 2021, 14 (12)
  • [34] Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0
    Lore Santoro
    L. Pitalot
    D. Trauchessec
    E. Mora-Ramirez
    P. O. Kotzki
    M. Bardiès
    E. Deshayes
    EJNMMI Research, 11
  • [35] Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0
    Santoro, Lore
    Pitalot, L.
    Trauchessec, D.
    Mora-Ramirez, E.
    Kotzki, P. O.
    Bardies, M.
    Deshayes, E.
    EJNMMI RESEARCH, 2021, 11 (01)
  • [36] Comparison of Voxel S-values and Monte Carlo Simulation in [177Lu]Lu-DOTA-TATE Quantification for Patient-Specific Dosimetry
    Rodrigues, C.
    Ferreira, P.
    Oliveira, F. P. M.
    Silva, A.
    Peralta, L.
    Costa, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S75 - S75
  • [37] A PBPK model for PRRT with [177Lu]Lu-DOTA-TATE: Comparison of model implementations in SAAM II and MATLAB/SimBiology
    Vasic, Valentina
    Gustafsson, Johan
    Nowshahr, Elham Yousefzadeh
    Stenvall, Anna
    Beer, Ambros J.
    Glatting, Gerhard
    Gleisner, Katarina Sjogreen
    PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS, 2024, 119
  • [38] Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours
    Geenen, Lorain
    Nonnekens, Julie
    Konijnenberg, Mark
    Baatout, Sarah
    De Jong, Marion
    Aerts, An
    NUCLEAR MEDICINE AND BIOLOGY, 2021, 102 : 1 - 11
  • [39] Improved prediction of haematological toxicity during [177Lu]Lu-DOTA-TATE therapy by optimising serial SPECT-CT red marrow dosimetry
    Tipping, J.
    Page, E.
    Calvert, N.
    Hamilton, D.
    Cullen, D.
    Price, E.
    Pells, S.
    Needham, G.
    Manoharan, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S239 - S239
  • [40] Radioligand Therapy with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
    Durma, Adam Daniel
    Saracyn, Marek
    Kolodziej, Maciej
    Jozwik-Plebanek, Katarzyna
    Dmochowska, Beata
    Mroz, Adrianna
    Zmudzki, Wawrzyniec
    Kaminski, Grzegorz
    PHARMACEUTICALS, 2023, 16 (09)